Abstract
An 82-year-old patient with high-risk prostate adenocarcinoma, previously treated with radiotherapy and hormone therapy, presented with biochemical recurrence, as evidenced by a prostate-specific antigen level of 10 ng/mL. A positron emission tomography/computed tomography (PET/CT) scan using 18F-prostate-specific membrane antigen (PSMA ) 1007 revealed significant uptake at the prostate apex and multiple hypermetabolic osseous lesions in the sternum and L3, suggestive of local recurrence and metastasis. However, several hypermetabolic foci in the abdominopelvic region raised suspicion for potential involvement of the lumbar-aortic lymph nodes due to their moderate to intense uptake. After further investigation, these findings were attributed to active aortic calcifications. This case highlights a rare cause of false-positive results in 18F-PSMA 1007 PET/CT imaging and underscores the need for additional evaluations, such as abdominopelvic magnetic resonance imaging and renal and phosphocalcic assessments, when such results are suspected.
Keywords:
Aortic calcifications, lymph nodes, 18F-PSMA1007
Ethics
Informed Consent: The institutional review board of our institute “Med V Military Teaching Hospital”, approved this publication, and the requirement to obtain informed consent was waived.
Authorship Contributions
Surgical and Medical Practices: S.N.O., Concept: S.N.O., O.A.S., A.D., Design: S.N.O., O.A.S., I.Z., Data Collection or Processing: S.N.O., O.A.S., I.Z., M.A., Analysis or Interpretation: S.N.O., I.Z., M.A., Y.B., A.D., Literature Search: S.N.O., M.A., Writing: S.N.O.
Conflict of Interest: No conflicts of interest were declared by the authors.
Financial Disclosure: The authors declare that this study has received no financial support.
References
1Afshar-Oromieh A, Babich JW, Kratochwil C, Giesel FL, Eisenhut M, Kopka K, Haberkorn U. The rise of PSMA ligands for diagnosis and therapy of prostate cancer. J Nucl Med. 2016;57:79S-89S.
2Yordanova A. The role of PSMA PET/CT in prostate cancer: imaging and beyond. Cancer Letters. 2016;382:205-213.
3Orevi M, Ben-Haim S, Abourbeh G, Chicheportiche A, Mishani E, Yutkin V, Gofrit ON. False positive findings of [18F]PSMA-1007 PET/CT in patients after radical prostatectomy with undetectable serum PSA Levels. Front Surg. 2022;9:943760.
4Moukaddam H, El Saheb G, Omran N, El Ghawi N, Abi Ghanem A, Haidar M. Case report: positive pitfalls of PSMA PET/CT: diagnostic challenges in degenerative bone lesions including MODIC type 1. Front Nucl Med. 2024;4:1451848.
5Galiza Barbosa F, Queiroz MA, Nunes RF, Bezerra ROF, Dalaqua M, Gustavo Rocha Resende R, Danil Faria Barbosa Lima E, Kobayashi M, Marins T, Santucci DF, Baroni RH. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging. 2020;20:23.
6Islam R, Desai S, Moran M, Golombos DM. The role of PSMA PET imaging in prostate cancer: current applications and future directions. Curr Urol Rep. 2025;26:46.
7Zaman MU, Fatima N, Zaman A, Sajid M, Zaman U, Zaman S. Diagnostic challenges in prostate cancer and 68Ga-PSMA PET imaging: a game changer? Asian Pac J Cancer Prev. 2017;18:2625-2628.
